Abbott Laboratories has reported sales of $10.6bn for the third quarter (Q3) of 2024, as against $10.4bn in Q2 2024, with ...
Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...
Continuous Glucose Monitoring Devices Market to reach a value of US$ 12.51 Bn by 2031 at a CAGR of 9.9% between 2024 and 2031 BURLINGAME, CA, UNITED STATES, October 15, 2024 /EINPresswire / -- A ...
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...
Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals. Click here to read ...
Continuous glucose monitoring enhanced by geriatric care principles reduced the duration of hypoglycemia without worsening ...
Senseonics’ Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 ...
Abbott’s earnings for the third quarter (Q3) of 2024 saw global sales reach $10.6 billion, a strong performance driven by the ...
Introduced in the late 1990s, continuous glucose monitoring (CGM) revolutionized diabetes care. Prior to CGM, home blood glucose monitoring (BGM) methodologies – which involve patients ...
Recent health news highlights various topics including Abbott's profit rise due to medical device sales, Trump's IVF comments ...
Continuous glucose monitors (CGM), once exclusive to diabetics, are now available over-the-counter, opening new possibilities ...